

REFERENCES

1. Alter MJ, Kruszon-Moran D, Nainan OV, et al.: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. *N Engl J Med* 1999;341:556-562.
2. Staadatmand F, Stinson FS, Grant BF, Dufour MC: Surveillance Report #49 – liver cirrhosis mortality in the United States, 1970-1995. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health
3. Davis GL, Albright JH, Cook SF, et al.: Projecting the future healthcare burden from hepatitis C in the United States. *Hepatology* 1998;28:390A.
4. El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. *N Engl J Med* 1999;340:745-750.
5. Kaplan LA: Determination and application of desirable analytical performance goals: the ISO/TC 212 approach. *Scand J Clin Lab Invest* 1999;59:479-482.
6. Fraser CG: The application of theoretical goals based on biological variation data in proficiency testing. *Arch Pathol Lab Med* 1988;112:404-415.
7. Westgard JO, Seehafer JJ, Barry PL: European specifications for imprecision and inaccuracy compared with operating specifications that assure the quality required by US CLIA proficiency-testing criteria. *Clin Chem* 1994;40:1228-1232.
8. Ricos C, Alvarez V, Cava F, et al.: Current databases on biological variation: pros, cons and progress. *Scand J Clin Lab Invest* 1999;59:491-500.
9. Skendzel LP, Barnett RN, Platt R: Medically useful criteria for analytic performance of laboratory tests. *Am J Clin Pathol* 1985;83:200-205.
10. Lott JA, Tholen DW, Massion CG: Proficiency testing of enzymes. Charting the way toward standardization. *Arch Pathol Lab Med* 1988;112:392-398.
11. Ross JW, Lawson NS: Analytic goals, concentration relationships, and state of the art for clinical laboratory precision. *Arch Pathol Lab Med* 1995;119:495-513.
12. Lott JA, Wolf PL. Alanine and aspartate aminotransferase (ALT and AST). *Clinical enzymology: a case-oriented approach*. Chicago, Year Book Medical Publishers, 1986,111-138.
13. Rej R. Measurement of aminotransferases: Part 1. Aspartate aminotransferase. *CRC Crit Rev Clin Lab Sci* 1984;21:99-106.

14. Price CP, Alberti KGMM: Biochemical Assessment of Liver Function. in Wright R, Alberti KGMM, Karran S, Millward-Sadler GH (eds.): Liver and Biliary Disease – Pathophysiology, Diagnosis, Management. London: W.B. Saunders, 1979,381-416.
15. Panteghini M: Aspartate aminotransferase isoenzymes. Clin Biochem 1990;23:311-319.
16. Siest G, Henry J, Schiele F, Young DS: Interpretation of Clinical Laboratory Tests: Reference Values and Their Biological Variation. Foster City, CA: Biomedical Publications, 1985.
17. Siest G, Schiele F, Galteau M-M, et al.: Aspartate aminotransferase and alanine aminotransferase activities in plasma: statistical distributions, individual variations, and reference values. Clin Chem 1975;21:1077-1087.
18. Cordoba J, O’Riordan K, Dupuis J, Borensztajn J, Blei AT: Diurnal variation of serum alanine transaminase activity in chronic liver disease. Hepatology 1999;28:1724-1725.
19. Fraser, CG: Biological variation in clinical chemistry: an update: collated data, 1988-1991. Arch Pathol Lab Med 1992;116:916-923.
21. Manolio TA, Burke GL, Savage PJ, et al.: Sex- and race-related differences in liver-associated serum chemistry tests in young adults in the CARDIA study. Clin Chem 1992;28:1853-1859.
22. Salvaggio A, Periti M, Miano L, Tavanelli M, Mazurati D: Body mass index and liver enzyme activity in serum. Clin Chem 1991;37:720-723.
23. Piton A, Poynard T, Imbert-Bismut F, et al.: Factors associated with serum alanine aminotransaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC group. Hepatology 1998;27:1213-1219.
24. Nuttall FQ, Jones B: Creatine kinase and glutamic oxolacetic transaminase activity in serum: kinetics of change with exercise and effect of physical conditioning. J Lab Clin Med 1968;51:257-261.
25. Dufour DR: Effects of habitual exercise on routine laboratory tests. Clin Chem 1998;44:136.
26. Ono T, Kitaguchi K, Takehara M, Shiiba M, Hayami K: Serum-constituents analyses: effect of duration and temperature of storage of clotted blood. Clin Chem 1981;27:35-38.

27. DiMagno EP, Corle D, O'Brien JF, Masnyk IJ, Go VL, Aamodt R: Effect of long-term freezer storage, thawing, and refreezing on selected constituents of serum. *Mayo Clin Proc* 1989;64:1226-1234.
28. Prasad R, Firkins K, Fiorello J: Stability of AST and ALT assays in Tris buffers. *Clin Chem* 1990;36:131-132.
29. Litin S, O'Brien JF, Pruett S, et al.: Macroenzyme as a cause of unexplained elevation of aspartate aminotransferase. *Mayo Clin Proc* 1987;62:681-687.
30. Mifflin TE, Bruns DE, Wrotnoski U, et al.: Macroamylase, macro creatine kinase, and other macroenzymes. *Clin Chem* 1985;31:1743-1748.
31. Nalpas B, Vassault A, Le Guillou A, et al.: Serum activity of mitochondrial aspartate aminotransferase: a sensitive marker of alcoholism with or without alcoholic hepatitis. *Hepatology* 1984;4:893-896.
32. Pol S, Nalpas B, Vassault A, et al.: Hepatic activity and mRNA expression of aspartate aminotransferase isoenzymes in alcoholic and nonalcoholic liver disease. *Hepatology* 1991;14:620-625.
33. Ludwig S, Kaplowitz N: Effect of serum pyridoxine deficiency on serum and liver transaminases in experimental liver injury in the rat. *Gastroenterology* 1980;79:545-549.
34. Zhou S-L, Gordon RE, Bradbury M, Stump D, Kiang C-L, Berk PD: Ethanol up-regulates fatty acid uptake and plasma membrane expression and export of mitochondrial aspartate aminotransferase in Hep G-2 cells. *Hepatology* 1998;27:1064-1074.
35. Bergmeyer HU, Scheibe P, Wahlefeld AW. Optimization of methods for aspartate aminotransferase and alanine aminotransferase. *Clin Chem* 1978;24:58-73.
36. Vanderlinde RE: Review of pyridoxal phosphate and the transaminases in liver disease. *Ann Clin Lab Sci* 1986;16:79-93.
37. Allman MA, Pang E, Yau DF, Stewart PM, Tiller DJ, Truswell AS: Elevated plasma vitamers of vitamin B6 in patients with chronic renal failure on regular hemodialysis. *Eur J Clin Nutr* 1992;46:679-683.
38. Dybkaer R, for the International Federation of Clinical Expert Panel on Theory of Reference Values and International Committee for Standardization in Haematology Standing Committee on Reference Values: Approved recommendation (1987) on the theory of reference values part 6. Presentation of observed values related to reference values. *Labmedica* 1988 (Apr/May), 27-30.
39. Lott JA, Tholen DW, Massion CG: Determination of reference ranges for serum enzymes via a large interlaboratory survey. *Arch Pathol Lab Med* 1987;111:9-15.

40. Moss DW. Multiple forms of acid and alkaline phosphatases: genetics, expression and tissue modification. *Clin Chim Acta* 1986;161:123-135.
41. Weiss MJ, Ray K, Henthorn PS, et al. Structure of the human liver/bone/kidney alkaline phosphatase gene. *J Biol Chem* 1988;263:12002-12010.
42. Clubb JS, Neale FC, Posen S. The behavior of infused placental alkaline phosphatase in human subjects. *J Lab Clin Med* 1965;66:493-507.
43. Moss DW. Physicochemical and pathophysiological factors in the release of membrane-bound alkaline phosphatase from cells. *Clin Chim Acta* 1997;257:133-140.
44. Schlaeger R, Haux D, Kattermann R. Studies on the mechanism of the increase in serum alkaline phosphatase activity in cholestasis: significance of the hepatic bile acid concentration for the leakage of alkaline phosphatase from rat liver. *Enzyme* 1982;28:3-13.
45. Bayer PM, Hotschek H, Knoth E. Intestinal alkaline phosphatase and the ABO blood group system: A new aspect. *Clin Chim Acta* 1980;108:81-7.
46. Gordon T: Factors associated with serum alkaline phosphatase level. *Arch Pathol Lab Med* 1993;117:187-190.
47. Young DS: *Effects of Preanalytical Variables on Clinical Laboratory Tests*, 2nd Ed.. Washington, DC: AACC Press, 1997.
48. Yamada N, Kido K, Hayashi S, et al.: Characteristics of blood biochemical constituents of pregnant women. *Acta Obstet Gynaec Jpn* 1977;29:447-450.
49. Dufour, DR: Effects of oral contraceptives on routine laboratory tests. *Clin Chem* 1998;44:137.
50. Bowers GN Jr, McComb RB, Kelley ML. Measurement of total alkaline phosphatase activity in human serum. *Sel Meth Clin Chem* 1977;8:31-9.
51. Gomez B, Ardakani S, Ju J, et al. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. *Clin Chem* 1995;41:1551-1553.
52. Anciaux ML, Pelletier AG, Attali P, Meduri B, Liguory C, Etienne JP: Prospective study of clinical and biochemical features of symptomatic choledocholithiasis. *Dig Dis Sci* 1986;31:449-453.
53. Sheeman M, Maythorn P. Predictive value of gamma-glutamyl transpeptidase in various liver diseases. In: Goldberg DM, Werner M, eds. *Progress in Clinical Enzymology*, New York, Masson, 1979,184-187.

54. Ratanasavanh D, Tazi A, Gaspart E. Hepatic gamma-glutamyl transferase release: effect of bile salt and membrane structure modification. *Advan Biochem Pharamacol* 1982;3:93-103.
55. Itoh S, Nakajima M: Liver gamma-glutamyl transferase activity in viral liver disease. *Digestion* 1986;33:121-125.
56. Nemesanszky E, Lott JA: Gamma-glutamyltransferase and its isoenzymes: progress and problems. *Clin Chem* 1985;31:797-803.
57. Nilssen O, Helge-Forde O, Brenn T: The Tromso study – distribution and population determinants of gamma-glutamyltransferase. *Am J Epidemiol* 1990;132:318-326.
58. Schiele F, Guilmin A-M, Detienne H, et al. Gamma-glutamyltransferase activity in plasma: statistical distributions, individual variations, and reference intervals. *Clin Chem* 1977;23:1023-1028.
59. Combes B, Shore GM, Cunningham FG, Walker FB, Shorey JW, Ware A: Serum gamma-glutamyl transpeptidase activity in viral hepatitis: suppression in pregnancy and by birth control pills. *Gastroenterology* 1977;72:271-274.
60. Young DS: *Effect of Drugs on Clinical Laboratory Tests*, 4th Ed. Washington, D.C.: AACC Press, 1995.
61. Moussavian SN, Becker RC, Piepmeyer JL, Mezey E, Bozian RC: Serum gamma-glutamyl transpeptidase and chronic alcoholism – influence of alcohol ingestion and liver disease. *Dig Dis Sci* 1985;30:211-214.
62. Hedworth-Whitty RB, Whitfield JB, Richardson RW. Serum gamma-glutamyltranspeptidase activity in myocardial ischaemia. *Brit Heart J* 1967;29:432-438.
63. Burrows S, Feldman W, McBride F: Serum gamma-glutamyl transpeptidase. Evaluation in screening of hospitalized patients. *Am J Clin Pathol* 1975;64:311-314.
64. Shaw LM, Stromme JH, London JL, Theodorsen L: International Federation of Clinical Chemistry. Scientific Committee, Analytical Section. Expert Panel on Enzymes. IFCC methods for measurement of enzymes. Part 4. IFCC methods for gamma-glutamyltransferase [(gamma-glutamyl)-peptide: amino acid gamma-glutamyltransferase, EC 2.3.2.2]. *Clin Chim Acta* 1983;135:315f-338f.
65. Chowdhury JR, Wolkoff AW, Chowdhury NR, Arias IM. Hereditary jaundice and disorders of bilirubin metabolism. In: *The metabolic and molecular bases of inherited disease*, Scriver CR, Beaudet AL, Sly WS, Valle D, Stanbury JB, Wyngaarden JB, Fredrickson DS, eds., New York, McGraw-Hill, Inc., 1995;2:2161-2208.

66. Berk PD, Martin JF, Blaschke TF, Scharchmidt BF, Plotz PH: Unconjugated hyperbilirubinemia: physiologic evaluation and experimental approaches to therapy. *Ann Intern Med* 1975;82:552-570.

67. Bloomer JR, Berk PD, Vergalla J, Berlin NI. Influence of albumin on the extravascular distribution of unconjugated bilirubin. *Clin Sci Mol Med* 1973;45:517-521.

68. McDonagh AF, Palma AA, Lauff JJ, Wu TW: Origin of mammalian biliprotein and rearrangement of bilirubin glucuronides in vivo in the rat. *J Clin Invest* 1984;74:763-770.

69. Fevery J, Blanckaert N: What can we learn from analysis of serum bilirubin. *J Hepatol* 1986;2:113-121.

70. Berk PD, Noyer C: Clinical chemistry and physiology of bilirubin. *Sem Liver Dis* 1994;14:346-355.

71. Zimmerman HJ: Intrahepatic cholestasis. *Arch Intern Med* 1979;139:1038-1045.

72. Van Hootegem P, Fevery J, Blanckaert N: Serum bilirubins in hepatobiliary disease: comparison with other liver function tests and changes in the portobstructive period. *Hepatology* 1985;5:112-117.

73. Bosma PJ, Chowdhury JR, Gantla BC, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's Syndrome. *N Engl J Med* 1995;333:1171-1175.

74. Persico P, Persico E, Bakker C, et al.: Hyperbilirubinemia in subjects with Gilbert syndrome (GS) mutations is determined by the rate of hepatic uptake of organic anions. *Hepatology* 1999;30:501A.

75. Thomsen HF, Hardt F, Juhl E. Diagnosis of Gilbert's Syndrome. *Scand J Gastroent* 1981;16:699-703.

76. Barrett PVD: Bilirubinemia and fasting. *N Engl J Med* 1970;283:823.

77. Dufour, DR: Effects of food ingestion on routine laboratory tests. *Clin Chem* 1998;44:136.

78. Carmel R, Wong ET, Weiner JM, Johson CS. Racial differences in serum total bilirubin levels in health and in disease (pernicious anemia). *JAMA* 1985;253:3416-3418.

79. Ihara H, Shino Y, Hashizume N, et al. Effect of light on total and direct bilirubin by an enzymatic bilirubin oxidase method. *J Anal Bio Sci* 1997;20:349-354.

80. Doumas BT, Wu T-W, Jendrzeczak: Delta bilirubin: absorption spectra, molar absorptivity, and reactivity in the diazo reaction. *Clin Chem* 1987;33:769-774
81. Doumas BT, Wu T-W. The measurement of bilirubin fractions in serum. *Crit Rev Clin Lab Sci* 1991;28:415-446.
82. Kubasik NP, Mayer TK, Bhaskar AG, Sine HE, D'Souza JP: The measurement of fractionated bilirubin by Ektachem film slides – method validation and comparison of conjugated bilirubin measurements with direct bilirubin in obstructive and hepatocellular jaundice. *Am J Clin Pathol* 1985;84:518-523.
83. Doumas BT, Peters T: Serum and urine albumin: a progress report on their measurement and clinical significance. *Clin Chim Acta* 1997;258:3-20.
84. Dufour, DR: Gender related differences in liver function and integrity tests. *Clin Chem* 1998;44:137.
85. McGinlay JM, Payne RB: Serum albumin by dye-binding: bromocresol green or bromocresol purple? *Ann Clin Biochem* 1988;25:417-421.
86. Beyer C, Boekhout M, van Iperen H: Bromocresol purple dye-binding and immunoturbidimetry for albumin measurement in plasma or serum of patients with renal failure. *Clin Chem* 1994;40:844-845.
87. Bush V, Reed RG: Bromocresol purple dye-binding methods underestimate albumin that is carrying covalently bound bilirubin. *Clin Chem* 1987;33:821-823.
88. Pascucci MW, Grisley DW, Rand RN: Electroimmunoassay of albumin in human serum: accuracy and long-term precision. *Clin Chem* 1983;29:1787-1790.
89. Ts'ao C, Swedlund J, Neofotistos D: Implications of use of low international sensitivity index thromboplastins in prothrombin time testing. *Arch Pathol Lab Med* 1994;118:1183-1187.
90. Taberner DA, Poller L, Thomson JM, Darby KV: Effect of international sensitivity index (ISI) of thromboplastins on precision of international normalised ratios (INR). *J Clin Pathol* 1989;42:92-96.
91. Kovacs MJ, Wong A, MacKinnon K, et al.: Assessment of the validity of the INR system for patients with liver impairment. *Thromb Haemost* 1994;71:727-730.
92. Robert A, Chazouilleres O: Prothrombin time in liver failure: time, ratio, activity percentage, or International Normalized Ratio? *Hepatology* 1996;24:1392-1394.

93. Blanchard RA, Furie BC, Jorgensen M, Kruger SF, Furie B: Acquired vitamin K-dependent carboxylation deficiency in liver disease. *N Engl J Med* 1981;305:242-248.
94. Dufour, DR, Teot, L: Laboratory identification of ischemic hepatitis (shock liver). *Clin Chem* 1988;34:1287.
95. Fuchs S, Bogomolski-Yahalom V, Paltiel O, Ackerman Z: Ischemic hepatitis: clinical and laboratory observations of 34 patients. *J Clin Gastroenterol* 1998;26:183-186.
96. Singer AJ, Carracio TR, Mofenson HC: The temporal profile of increased transaminase levels in patients with acetaminophen-induced liver dysfunction. *Ann Emerg Med* 1995;26:49-53.
97. Willner IR, Uhl MD, Howard SC, Williams EQ, Riely CA, Waters B: Serious hepatitis A: an analysis of patients hospitalized during an epidemic in the United States. *Ann Intern Med* 1998;128:111-114.
98. Mendenhall CL and the VA Cooperative Study Group on Alcoholic Hepatitis: Alcoholic hepatitis. *Clin Gastroenterol* 1981;10:417-441.
99. O'Grady JG, Alexander GJM, Hayllar KM, Williams R: Early indicators of prognosis in fulminant hepatic failure. *Gastroenterology* 1989;97:4439-4445.
100. Bonacini M, Hadi G, Govindarajan S, Lindsay KL: Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C infection. *Am J Gastroenterol* 1997;92:1302-1304.
101. Baglin T, Luddington R: Reliability of delayed INR determination: implications for decentralized anticoagulant care with off-site blood sampling. *Br. J. Haematol* 1997;96:431-434.
102. Adcock DM, Kressen DC, Marlar RA: Effect of 3.2% vs. 3.8% sodium citrate on routine coagulation testing. *Am J Clin Pathol* 1997;107:105-110.
103. Cunningham MTA, Johnson GF, Pennell BJ, Olson JD: The reliability of manufacturer-determined, instrument specific international sensitivity index values for calculating the international normalized ratio. *Am J Clin Pathol* 1994;102:128-133.
104. Stevenson KJ, Craig S, Dufty JMK, Taberner DA: System ISI calibration: a universally applicable scheme is possible only when coumarin plasma calibrants are used. *Br J Haematol* 1997;96:435-441.
105. Lassen JF, Kjeldsen J, Antonsen S, Petersen PH, Brandslund I: Interpretation of serial measurements of international normalized ratio for prothrombin times in monitoring oral anticoagulant therapy. *Clin Chem* 1995;41:1171-1176.

106. Poller L: Screening INR deviation of local prothrombin time systems. *J Clin Pathol* 1998;51:356-359.
107. Johnson M, Brigder M: A cross-Canada survey of prothrombin time testing – does the establishment of local ISI values improve the accuracy of International Normalized Ratio reporting? *Am J Clin Pathol* 1998;110:683-690.
108. Miyaji H, Ito S, Azuma T, et al.: Effects of *Helicobacter pylori* eradication therapy on hyperammonemia in patients with liver cirrhosis. *Gut* 1997;40:726-730.
110. Batshaw ML: Inborn errors of urea synthesis. *Ann Neurol* 1994;35:133-141.
111. Heubi JE, Daugherty CC, Partin JS, Partin JC, Schubert WK: Grade 1 Reye's syndrome – outcome and predictors of progression to deeper coma grades. *N Engl J Med* 1984;311:1539-1542.
112. Stahl J: Studies of the blood ammonia in liver disease – its diagnostic, prognostic, and therapeutic significance. *Ann Intern Med* 1963;58:1-23.
113. Butterworth RF, Giguere JF, Michaud J, Lavoie J, Layrargues GP: Ammonia: key factor in the pathogenesis of hepatic encephalopathy. *Neurochem Pathol* 1987;6:1-12.
114. Muting D, Kalk JF, Fischer R, Wuzel H, Reikowski J: Hepatic detoxification and hepatic function in chronic active hepatitis with and without cirrhosis. *Dig Dis Sci* 1988;33:41-46.
115. McClain CJ, Zieve L, Doizaki WM, Gilberstadt S, Onstad GR: Blood methanetriol in alcoholic liver disease with and without hepatic encephalopathy. *Gut* 1980;21:318-323.
116. Jones EA, Basile AS: The involvement of ammonia with the mechanisms that enhance GABA-ergic neurotransmission in hepatic failure. *Adv Exp Med Biol* 1997;420:75-83.
117. Norenberg MD, Itzhak Y, Bender AS: The peripheral benzodiazepine receptor and neurosteroids in hepatic encephalopathy. *Adv Exp Med Biol* 1997;420:95-111.
118. Chamuleau RAFM, Vogels BAPM: Hyperammonemia without portal systemic shunting does not resemble hepatic encephalopathy. *Adv Exp Med Biol* 1997;420:173-183.
119. Diaz J, Tornel PL, Martinez P: Reference intervals for blood ammonia in healthy subjects, determined by microdiffusion. *Clin Chem* 1995;41:1048.

120. Huizenga JR, Tangerman A, Gips CH: Determination of blood ammonia in biological fluids. *Ann Clin Biochem* 1994;31:529-543.
121. Derave W, Bouckaert J, Pannier JL: Gender differences in blood ammonia response during exercise. *Arch Physiol Biochem* 1997;105:203-209.
122. da Fonseca-Wollheim F: Preanalytical increase of ammonia in blood specimens from healthy subjects. *Clin Chem* 1990;36:1483-1487.
123. Davies SM, Szabo E, Wagner JE, Ramsay NK, Weisdorf DJ: Idiopathic hyperammonemia: a frequently lethal complication of bone marrow transplantation. *Bone Marrow Transplant* 1996;17:1119-1125.
124. Xu SR, Yao EG, Dong ZR, et al.: Plasma ammonia in patients with acute leukemia. *Chin Med J* 1992;105:713-716.
125. Altunbasak S, Baytok V, Tasouji M, Herguner O, Burgut R, Kayrine L: Asymptomatic hyperammonemia in children treated with valproic acid. *J Child Neurol* 1997;12:461-463.
126. Shepard RL, Kraus SE, Babayan RK, Sirosky MB: The role of ammonia toxicity in the post transurethral prostatectomy syndrome. *Br J Urol* 1987;60:349-351.
127. Ammonia. College of American Pathologists, 325 Waukegan Road, Northfield, IL 60093, Chemistry Survey Set C-B, 1999,73.
128. Stapleton JT: Host immune response to hepatitis A virus. *J Infect Dis* 1995;175(Suppl 1):S9-S14.
129. Skinhoj P, Mikkelsen F, Hollinger FB: Hepatitis A in Greenland: importance of specific antibody testing in epidemiologic surveillance. *Am J Epidemiol* 1977;105:140-147.
130. Koff RS: Seroepidemiology of hepatitis A in the United States. *J Infect Dis* 1995;171(Suppl 1):S19-S23.
131. Goubau P, Gan Gerven V, Safary A: Effect of virus strain and antigen dose on immunogenicity and reactogenicity of an inactivated hepatitis A vaccine. *Vaccine* 1992;10(Suppl 1):S114-S118.
132. Totos G, Gizaris V, Papaevangelou G: Hepatitis A vaccine: persistence of antibodies 5 years after the first vaccination. *Vaccine* 1997;15:1252-1253.
133. Hollinger FB, Dreesman GR: Hepatitis viruses. In Rose NR, de Macario EC, Folds JD, Lane HC, Nakamura RM (eds.): Manual of Clinical Laboratory Immunology, 5th ed. Washington DC, American Society for Microbiology, 1997

146. Lorient MA, Marcellin P, Walker F, et al.: Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg. *J Hepatol* 1997;27:251-258.
147. Marusawa H, Uemoto S, Hijikata M, et al.: Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. *Hepatology* 2000;31:488-495.
148. Aoyagi K, Ohue C, Iida K, et al.: Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. *J Clin Microbiol* 1999;37:1802-1808.
149. Alter HJ: New kit on the block: evaluation of second-generation assays for detection of antibody to the hepatitis C virus. *Hepatology* 1992;15:340-353.
150. Lu RH, Hwang SJ, Chan CY, Chang FY, Lee SD: Quantitative measurement of serum HCV-RNA in patients with chronic hepatitis C: comparison between Amplicor HCV monitor system and branched DNA signal amplification assay. *J Clin Lab Anal* 1998;12:121-125.
151. Barrera JM, Francis B, Ercilla G, et al.: Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. *Vox Sang* 1995;68:15-18.
152. Barrera JM, Bruguera M, Ercilla MG, et al.: Persistent hepatitis C viremia after acute self-limited posttransfusion hepatitis. *Hepatology* 1995;21:639-644.
153. Seeff LB, the NHLBI Study Group: Mortality and morbidity of transfusion-associated non-A, non-B hepatitis and type C hepatitis: and NHLBI multi-center study. *Hepatology* 1994;20:204A.
154. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U: Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. *Hepatology* 2000;32:91-96.
155. Mast AF, Hwang L-Y, Seto D, Nolte FS, Kelly MG, Alter MJ: Perinatal hepatitis C virus transmission: maternal risk factors and optimal timing of diagnosis. *Hepatology* 1999;30:499A.
156. Thomas SL, Newell ML, Peckham CS, Ades AE, Hall AJ: Use of polymerase chain reaction and antibody tests in the diagnosis of vertically transmitted hepatitis C virus infection. *Eur. J. Clin. Microbiol. Infect. Dis.* 1997;16:711-719.
157. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL: Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. *Hepatology* 1999;29:908-914.

158. Pawlotsky J-M, Lonjon I, Hezode C, et al.: What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? *Hepatology* 1998;27:1700-1702.
158. Ravaggi A, Biasin MR, Infantolino D, Cariani E: Comparison of competitive and non-competitive reverse transcriptase-polymerase chain reaction (RT-PCR) for the quantification of hepatitis C virus (HCV) RNA. *J Virol Methods* 1997;65A:123-129.
159. Lunel F, Cresta P, Vitour D, et al.: Comparative evaluation of hepatitis C virus RNA quantitation by branched DNA, NASBA, and Monitor assays. *Hepatology* 1999;29:528-535.
160. Davis GL, Lau JY, Urdea MS, et al.: Quantitative detection of hepatitis C virus RNA with a solid-phase signal amplification assay: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. *Hepatology* 1994;19:1337-41.
161. Saldanha J, Lelie N, Heath A: Establishment of the first international standard for nucleic acid amplification technology assays for HCV RNA. *Vox Sanguinis* 1999;76:149-158.
162. Bukh J, Miller RH, Purcell RH: Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. *Semin Liver Dis* 1995;15:41-63.
163. Reddy KR, Hoofnagle JH, Tong MJ, et al.: Racial differences in response to therapy with interferon in chronic hepatitis C. *Hepatology* 1999;30:787-893.
164. Forns X, Bukh J: Methods for determining the hepatitis C virus genotype. *Viral Hepatitis* 1998;4: 1-19.
165. Germer JJ, Rys PH, Thorvilson JN, Pershing DH: Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test. *J Clin Microbiol* 1999;37:2625-2630.
166. Marshall DJ, Heisler LM, Lyamichev V, et al.: Determination of hepatitis C virus genotype in the United States by cleavage fragment length polymorphism analysis. *J Clin Microbiol* 1997;35:3156-3162.
167. Pawlotsky JM, Prescott L, Simmonds P, et al.: Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay. *J Clin Microbiol* 1997;35:1734-1739.
168. Lau JY, Mizokami M, Kolberg JA, et al.: Application of six hepatitis C genotyping systems to sera from chronic hepatitis C patients in the United States. *J Infect Dis* 1995;171:282-289.

169. Rizetto M, Ponzetto A, Forzani I: Epidemiology of hepatitis delta virus: overview. *Prog Clin Biol Res* 1991;364:1-20.
170. Erker JC, Dessai SM, Schlauder GG, Dawson GJ, Mushawar IK: A hepatitis E variant from the United States: molecular characterization and transmission in cynomolgus macaques. *J Gen Virol* 1999;80:681-690.
171. Yarbrough, PO, Tam AW, Gabor K, et al.: Assay development of diagnostic tests for hepatitis E. In Nishioka K, Suzuki H, Mishiro S, Oda T (eds.): Viral Hepatitis and Liver Disease. Tokyo, Japan, Springer-Verlag, 1994.
172. Mast EE, Alter MJ, Holland PV, Purcell RH: Evaluation of assays for antibody to hepatitis E virus by a serum panel. Hepatitis E Virus Antibody Serum Panel Evaluation Group. *Hepatology* 1998;27:857-861.
173. Thomas DL, Yarbough PO, Vlahov D, et al.: Seroreactivity to hepatitis E virus in areas where the disease is not endemic. *J Clin Microbiol* 1997;35:1244-1247.
174. Ellis G, Goldberg DM, Spooner RJ, Ward AM: Serum enzyme tests in diseases of the liver and biliary tree. *Am J Clin Pathol* 1978;70:248-258.
175. Rozen P, Korn RJ, Zimmerman HJ: Computer analysis of liver function tests and their interrelationship in 347 cases of viral hepatitis. *Isr J Med Sci* 1970;6:67-79.
- 175a. Hepatitis Surveillance Report No. 56. Atlanta: Centers for Disease Control and Prevention, 1995, 36p.
176. Whitehead MW, Hawkes ND, Hainsworth I, Kingham JGC: A prospective study of the causes of notably raised aspartate aminotransferase of liver origin. *Gut* 1999;45:129-133.
177. Anciaux ML, Pelletier AG, Attali P, Meduri B, Liguory C, Etienne JP: Prospective study of clinical and biochemical features of symptomatic choledocholithiasis. *Dig Dis Sci* 1986;31:449-453.
178. Fortson WC, Tedesco FJ, Starnes EC, Shaw CT: Marked elevation of serum transaminase activity associated with extrahepatic biliary tract disease. *J Clin Gastroenterol* 1985;7:502-505.
179. Mihas AA, Doos WG, Spenny JG: Alcoholic hepatitis – a clinical and pathological study of 142 cases. *J Chronic Dis* 1978;31:461-472.
180. Goldberg S, Mendenhall C, Anderson S, et al.: VA Cooperative Study on Alcoholic Hepatitis. IV. The significance of clinically mild alcoholic hepatitis – describing the population with minimal hyperbilirubinemia. *Am J Gastroenterol* 1986;81:1029-1034.

181. Stewart JS, Farrow LJ, Clifford RE, et al.: A three-year survey of viral hepatitis in West London. *Q J Med* 1978;47:365-84.
182. Lednar WM, Lemon SM, Kirkpatrick JW, Redfield RR, Fields ML, Kelley PW: Frequency of illness associated with epidemic hepatitis A virus infections in adults. *Am J Epidemiol* 1985;122:226-233.
183. Gitlin N: Hepatitis B: diagnosis, prevention, and treatment. *Clin Chem* 1997;43:1500-1506.
184. McMahon BJ, Alward WL, Hall DB, et al.: Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. *J Infect Dis* 1985;151:599-603.
185. Hoofnagle JH: Hepatitis C: the clinical spectrum of disease. *Hepatology* 1997;26(Suppl 1):15S-20S.
186. Seeff LB, Wright EC, Zimmerman HJ, McCollum: VA Cooperative study of post-transfusion hepatitis, 1969-1974: incidence and characteristics of hepatitis and responsible risk factors. *Am J Med Sci* 1975;270:355-362.
187. Borsch G, Baier J, Glocke M, Nathusius W, Gerhardt W: Graphical analysis of laboratory data in the differential diagnosis of cholestasis: a computer-assisted prospective study. *J Clin Chem Clin Biochem* 1988;26:509-519.
188. Kenny-Walsh E, for the Irish Hepatology Research Group: Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. *N Engl J Med* 1999;340:1228-1233.
189. Vogt M, Lang T, Frosner G, et al.: Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood donor screening. *N Engl J Med* 1999;341:866-870.
190. Gitlin N, Serio KM: Ischemic hepatitis: widening horizons. *Am J Gastroenterol* 1992;87:831-836.
191. Tygstrup N, Ranek L: Assessment of prognosis in fulminant hepatic failure. *Semin Liv Dis* 1986;6:129-137.
192. Harrison PM, O'Grady JG, Keays RT, Alexander GJ, Williams R: Serial prothrombin time as prognostic indicator in paracetamol induced fulminant hepatic failure. *BMJ* 1990;301:964-968.
193. Noskin GA: Prevention, diagnosis, and management of viral hepatitis: a guide for primary care physicians. *Arch Fam Med* 1995;4:923-934.

194. Lemon SM, Brown CD, Brooks DS, Simms TE, Bancroft WH: Specific immunoglobulin M response to hepatitis A virus determined by solid phase radioimmunoassay. *Infect Immun* 1980;28:927-936.
195. Gretch DR, dela Rosa C, Carithers RL, Wilson RA, Williams B, Corey L. Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications. *Ann Intern Med* 1995;123:3211-329.
196. Alter MJ, Margolis HS, Krawczynski K, et al.: The natural history of community acquired hepatitis C in the United States. *N Engl J Med* 1992;327:1899-1905.
197. London WT, Evans AA: The epidemiology of hepatitis viruses B, C, and D. *Clin Lab Med* 1996;16:251-171.
198. Zimmerman HJ: Hepatotoxicology: The adverse effects of drugs and other chemicals on the liver, 2nd Edition. Philadelphia: J. B. Lippincot, 1999.
199. Fry SW, Seeff LB: Hepatotoxicity of analgesics and antiinflammatory agents. *Gastroenterol Clin North Am* 1995;24:875-905.
200. Zimmerman HJ, Maddrey WC: Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. *Hepatology* 1995;22:767-773.
- 200a. Johnson RD, O'Connor ML, Kerr RM: Extreme serum elevations of aspartate aminotransferase. *Am J Gastroenterol* 1995;90:1244-1245.
201. Shilsky ML: Wilson disease: genetic basis of copper toxicity and natural history. *Semin Liv Dis* 1996;16:83-95.
202. Steindl, P, Ferenci P, Dienes HP, et al.: Wilson's disease in patients presenting with liver disease: a diagnostic challenge. *Gastroenterology* 1997;113:212-218.
203. Berman DH, Leventhal RI, Gavaler JS, Cadoff EM, Van Thiel DH: Clinical differentiation of fulminant Wilsonian hepatitis from other causes of hepatic failure. *Gastroenterology* 1991;100:1129-1134.
204. Crapper RM, Bhathal PS, Mackay IR, Frazer IH: "Acute" autoimmune hepatitis. *Digestion* 1986;34:216-225.
205. Amontree JS, Stuart TD, Bredfeldt JE: Autoimmune chronic active hepatitis masquerading as acute hepatitis. *J Clin Gastroenterol* 1989;11:303-307.
206. Johnson PJ, McFarlane IG, Alvarez F, et al.: Meeting report: International Autoimmune Hepatitis Group. *Hepatology* 1993;18:998-1008.

207. Horwitz CA, Burke MD, Grimes P, Tombers J: Hepatic function in mononucleosis induced by Epstein-Barr virus and cytomegalovirus. *Clin Chem* 1980;26:243-246.
208. Liaw YF, Chu CM, Su IJ, Huang MJ, Lin DY, Chang-Chien CS: Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. *Gastroenterology* 1983;84:216-219.
209. Yuki N, Hayashi N, Moribe T, et al.: Relation of disease activity during chronic hepatitis C infection to complexity of hypervariable region 1 quasispecies. *Hepatology* 1997;25:439-444.
210. Tong MJ, el-Farra NS, Crew MI: Clinical manifestations of hepatitis A. Recent experience in a community teaching hospital. *J Infect Dis* 1995;171 Suppl 1:S15-S18.
211. Inglesby TV, Rai R, Astemborski J, et al.: A prospective community-based evaluation of liver enzymes in individuals with hepatitis C after drug use. *Hepatology* 1999;29:590-596.
212. de Franchis R, Meucci G, Vecchi M, Tatarella M, Colombo M, Del Ninno E, et al.: The natural history of asymptomatic hepatitis B surface antigen carriers. *Ann Intern Med* 1993;118:191-4.
213. Weiss JS, Gautman A, Lauff JJ, et al.: The clinical importance of a protein-bound fraction of serum bilirubin in patients with hyperbilirubinemia. *N Engl J Med* 1983;309:147-150.
214. Van Hootehem P, Fevery J, Blanckaert N: Serum bilirubins in hepatobiliary disease: comparison with other liver function tests and changes in the postobstructive period. *Hepatology* 1985;5:112-117.
215. Gordon SC, Reddy KR, Schiff L, Schiff ER: Prolonged intrahepatic cholestasis secondary to acute hepatitis A. *Ann Intern Med* 1984;101:635-637.
216. Van Ness MM, Diehl AM: Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? *Ann Intern Med* 1989;111:473-478.
217. Mathurin P, Moussali J, Cadranel J-F, et al.: Slow progression rate of fibrosis in hepatitis C patients with persistently normal alanine aminotransferase activity. *Hepatology* 1998;27:568-572.
218. Centers for Disease Control and Prevention: Recommendations for the prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. *MMWR* 1998;47(No.RR-19), 1-39.

219. Quinn PG, Johnston DE: Detection of chronic liver disease: costs and benefits. *Gastroenterologist* 1997;5:58-77.
220. Sheth SG, Glamm SL, Gordon FD, Chopra S: AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. *Am J Gastroenterol* 1998;93:44-48.
221. Hultcrantz R, Glaumann H, Lindberg G, Nilsson LH: Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. *Scand J Gastroenterol* 1986;21:109-113.
222. Friedman LS, Dienstag JL, Watkins E, et al.: Evaluation of blood donors with elevated serum alanine aminotransferase levels. *Ann Intern Med* 1987;107:137-144.
223. Kundrotas LW, Clement DJ: Serum alanine aminotransferase (ALT) elevation in asymptomatic US Air Force basic trainee blood donors. *Dig Dis Sci* 1993;38:2145-2150.
224. de Franchis R, Meucci G, Vecchi M, Tatarella M, Colombo M, Del Ninno E, et al.: The natural history of asymptomatic hepatitis B surface antigen carriers. *Ann Intern Med* 1993;118:191-4.
225. McMahon BJ, Christensen C, Gretch D, et al.: Alanine aminotransferase (ALT) levels over time in anti-HCV-positive persons who are HCV RNA positive compared with persons who are HCV RNA negative but RIBA positive. *Hepatology* 1999;30:358A.
226. Cauza E, Maier-Dobersberger T, Polli C, Kaserer K, Kramer L, Ferenci P: Screening for Wilson's disease in patients with liver diseases by serum ceruloplasmin. *J Hepatol* 1997;27:358-362.
227. Mathiesen UL, Franzen LE, Fryden A, Foberg U, Bodemar G: The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. *Scand J Gastroenterol* 1999;34:85-91.
228. Sheth SG, Gordon FD, Chopra S: Nonalcoholic steatohepatitis. *Ann Intern Med* 1997;126:137-145.
229. Bacon BR, Farahvash MJ, Janney CJ, Neuschwander-Tetri BA: Nonalcoholic steatohepatitis: an expanded clinical entity. *Gastroenterology* 1994;107:1103-1109.
230. Palmer M, Schaffner F: Effect of weight reduction on hepatic abnormalities in overweight patients. *Gastroenterology* 1990;99:1408-1413.
231. McLaren CE, Gordeuk VR, Looker AC, et al.: Prevalence of heterozygotes for hemochromatosis in the white population of the United States. *Blood* 1995;86:2021-2027.

232. Feder JN, Gnirke A, Thomas W, et al.: A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. *Nat Genet* 1996;13:399-408.
233. Milman N, Albeck MJ: Distinction between homozygous and heterozygous subjects with hereditary haemochromatosis using iron status markers and receiver operating characteristic (ROC) analysis. *Eur J Clin Chem Clin Biochem* 1995;33:95-98.
234. Witte DL: Mild liver enzyme abnormalities: eliminating hemochromatosis as cause. *Clin Chem* 1997;53:1535-1538.
235. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW: A population-based study of the clinical expression of the hemochromatosis gene. *N Engl J Med* 1999;341:718-724.
236. Adams PC, Kertesz AE, McLaren CE, Barr R, Bamford A, Chakrabarti S: Population screening for hemochromatosis: a comparison of unbound iron binding capacity, transferrin saturation, and C282Y genotyping in 5,211 blood donors. *Hepatology* 2000;31:1160-1164.
237. Bacon BR, Powell LW, Adams PC, Kresina TF, Hoofnagle JH: Molecular medicine and hemochromatosis: at the crossroads. *Gastroenterology* 1999;116:193-207.
238. Witte DL, Crosby WH, Edwards CQ, Fairbanks VG, Mitros FA: Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis. *Clin Chim Acta* 1996;245:139-200.
239. Adams PC, Gregor JC, Kertesz AE, Valberg LS: Screening blood donors for hereditary hemochromatosis: decision analysis model based on a 30-year database. *Gastroenterology* 1995;109:177-188.
240. Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW: The Wilson disease gene is a putative copper transporting P-type ATP-ase similar to the Menkes gene. *Nature Genet* 1993;5:327-337.
241. Gibbs K, Walshe JM: A study of the caeruloplasmic concentrations found in 75 patients with Wilson's disease, their kindreds, and various control groups. *Q J Med* 1979;48:447-463.
242. Dufour J-F, Kaplan MM: Muddying the water: Wilson's disease challenges will not soon disappear. *Gastroenterology* 1997;113:348-350.
243. Czaja AJ, Carpenter HA, Manns MP: Antibodies to soluble liver antigen, P450II5, and mitochondrial complexes in chronic hepatitis. *Gastroenterology* 1993;105:1522-1528.

244. Czaja AJ: Autoimmune hepatitis: evolving concepts and treatment strategies. *Dig Dis Sci* 1995;40:435-456.
245. Czaja AJ, Magrin S, Fabiano C, et al.: Hepatitis C virus infection as a determinant of behavior in type I autoimmune hepatitis. *Dig Dis Sci* 1995;40:33-40.
246. Czaja AJ, Taswell HF, Rakela J, Rabe D: Duration and specificity of antibodies to hepatitis C virus in chronic active hepatitis. *Gastroenterology* 1992;102:1675-1679.
247. Neuberger J: Primary biliary cirrhosis. *Lancet* 1997;350:875-879.
248. Yeaman SJ, Fussey SPM, Danner DJ, James OFW, Mutimer DJ, Bassendine MF: Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens. *Lancet* 1988;I:1067-1070.
249. Chazouilleres O, Wendum d, Serfaty L, Montembault S, Rosmordue O, Poupon R: Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. *Hepatology* 1998;28:296-301.
250. Lohse AW, Meyer zum Buschenfelde K-H, Franz B, Kanzler S, Gerken G, Dienes H-P: Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitis form of PBC in genetically susceptible individuals. *Hepatology* 1999;29:1078-1084.
251. Ponsioen CI, Tytgat GN: Primary sclerosing cholangitis: a clinical review. *Am J Gastroenterol* 1998;93:515-523.
252. Mudder AHL, Horst G, Haagsma EB, et al.: Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. *Hepatology* 1993;17:411-417.
253. Chapman RW, Cottone M, Selby WS, et al.: Serum autoantibodies, ulcerative colitis, and primary sclerosing cholangitis. *Gut* 1986;27:86-91.
254. Roozendaal C, Van Milligen de Wit M, Haagsma EB, et al.: Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: defined specificities may be associated with distinct clinical features. *Am J Med* 1998;105:393-399.
255. Carell RW, Jeppson JQ, Laurell CB: Structure and variation of human alpha-1-antitrypsin. *Nature* 1982;298:239-334.
256. Propst T, Propst A, Dietze O, Judmaier G, Braunsteiner H, Vogel W: Alpha-1-antitrypsin deficiency and liver disease. *Dig Dis* 1994;12:139-149.
257. Sveger T: The natural history of liver disease in alpha-1-antitrypsin deficient children. *Acta Paediatr Scand* 1988;77:847-851.

258. Graziadel IW, Joseph JJ, Wiesner RH, Therneau TM, Batts KP, Porayko MK: Increased risk of chronic liver failure in adults with heterozygous α_1 -antitrypsin deficiency. *Hepatology* 1998;28:1058-1063.
259. Fisher RL, Taylor L, Sherlock S: α -1-antitrypsin deficiency in liver disease: the extent of the problem. *Gastroenterology* 1976;71:646-651.
260. Propst T, Propst A, Dietze O, Judmaier G, Braunsteiner H, Vogel W.: High prevalence of viral infection in adults with homozygous and heterozygous α_1 -antitrypsin deficiency and chronic liver disease. *Ann Intern Med* 1992;117:641-645.
261. Hodges JR, Millward-Sadler GH, Baarbatis C, Wright R: Heterozygous MZ α_1 -antitrypsin deficiency in adults with chronic active hepatitis and cryptogenic cirrhosis. *N Engl J Med* 1981;304:557-560.
262. Linnen J, Wages J, Zhang-Keck Z, Fryk KE, Krawczynsky KZ, Aher H: Molecular clone in disease association of hepatitis G virus. A transruision transmissible agent. *Science* 1996;271:505-508.
263. Brandhagen DJ, Gross JB, Poterucha JJ, et al.: The clinical significance of simultaneous infection with hepatitis G virus in patients with chronic hepatitis C. *Am J Gastroenterol* 1999;94:1000-1005.
264. Hollingsworth RC, Minton EJ, Fraser-Moodie C, et al.: Hepatitis G infection: role in cryptogenic liver disease and primary liver cancer in the UK. Trent hepatitis C virus study group. *J Viral Hepat* 1998;4:165-169.
265. Laskus T, Radkowski M, Wang LF, Vargas H, Rakela J: Lack of evidence for hepatitis G virus replication in the livers of patients coinfectd with hepatitis C and G viruses. *J Virol* 1997;71:7804-7806.
266. Nishizawa AT, Okamoto H, Konishi K, Yoshizawa H, Miyakawa Y, Mayumi M: A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. *Biochem Biophys Res Commun* 1997;241:92-97.
267. Charlton M, Adjei P, Poterucha J, et al.: TT-virus infection in North American blood donors, patients withfulminant hepatic failure, and cryptogenic cirrhosis. *Hepatology* 1998;28:839-842.
268. Matsumoto A, Yeo AET, Shih JWK, Tanaka E, Kiyosawa K, Alter HJ: Transfusion-associated TT virus infection and its relationship to liver disease. *Hepatology* 1999;30:283-288.

269. Kanda T, Yokosuka O, Ikeuchi T, et al.: The role of TT virus infection in acute hepatitis. *Hepatology* 1999;29:1905-1908.
270. Alter HJ, Conry-Cantilena C, Melpolder J, et al.: Hepatitis C in asymptomatic blood donors. *Hepatology* 1997;26(Suppl 1):29S-33S.
270. Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB: Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. *Ann Intern Med* 1981;94:744-748.
271. Brown SD, Barbara AJ, Lambert T, Wilson DV: Spontaneous loss of HBeAg and development of anti-HBe during long-term follow-up of blood donors found to be HBsAg positive. *Br J Biomed Sci* 1995;52:106-109.
272. Lok AS, Ghany MG, Watson G, Ayola B: Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B. *J Viral Hepat* 1998;5:171-178.
273. Bernard F, Raymond G, Willems B, Villeneuve JP: Quantitative assessment of serum hepatitis B e antigen, IgM hepatitis B core antibody and HBV DNA in monitoring the response to treatment in patients with chronic hepatitis B. *J Viral Hepat* 1997;4:265-272.
274. Dienstag JL, Perillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M: A preliminary trial of lamivudine for chronic hepatitis B infection. *N Engl J Med* 1995;333:1704-1705.
275. Shobokshi OA, Serebour FE, Skakni L: Hepatitis B surface gene mutants and their emerging role in the efficacy of HBV vaccination programs. *Ann Saudi Med* 1999;19:87-92.
276. Lorient MA, Marcellin P, Walker F, et al.: Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg. *J Hepatol* 1997;27:251-258.
277. Omata M: Treatment of chronic hepatitis B infection. *N Engl J Med* 1998;339:114-115.
278. Lai C-L, Chien R-N, Leung NWY, Chang T-T, Guan R, Tai D-I, et al.: A one-year trial of lamivudine for chronic hepatitis B. *N Engl J Med* 1998;339:61-68.
279. Nguyen TT, Sedghi-Vaziri A, Wilkes LB, et al.: Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. *J Viral Hepat* 1996;3:75-78.

281. Fanning L: Natural fluctuations of hepatitis C viral load in a homogeneous patient population: a prospective study. *Hepatology* 2000;31:225-229.
282. Pontisso P, Bellati G, Brunetto M, Et al.: Hepatitis C virus profiles in chronically infected individuals: do they relate to disease activity? *Hepatology* 1999;29:585-589.
283. Beld M, Penning M, McMorow M, Gorgels J, van den Hoek A, Goudsmit J: Different hepatitis C virus (HCV) RNA load profiles following seroconversion among injecting drug users without correlation with HCV genotype and serum alanine aminotransferase levels. *J Clin Microbiol* 1998;36:872-877.
284. McHutchison JG, Gordon SC, Schiff ER, et al.: Interferon alfa-2b or in combination with ribavirin as initial treatment for chronic hepatitis C. *N Engl J Med* 1998;339:1485-1492.
285. Poynard T, Marcellin S, Lee SS, et al.: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). *Lancet* 1998;352:1426-1432.
286. Poynard T, McHutchison J, Goodman Z, Ling M-H, Albrecht J for the ALGOVIRC Project Group: Is an "A la Carte" combination interferon alfa-2b plus ribavirin regimen possible for first line treatment in patients with chronic hepatitis C? *Hepatology* 2000;31:211-218.
287. Camma C, Giunta M, Pinzello G, Morabito A, Verderio P, Pagliaro L: Chronic hepatitis C and interferon alpha: conventional and cumulative meta-analyses of randomized clinical trials. *Am J Gastroenterol* 1999;94:581-595.
288. Management of Hepatitis C. NIH Consensus Statement 1997 Mar 24-26: 15(3):1-41.
289. Consensus Statement: EASL international consensus conference on hepatitis C. *J Hepatol* 1999;30:956-961.
290. Haber MM, West AB, Haber AD, Reuben A: Relationship of aminotransferases to liver histological status in chronic hepatitis C. *Am J Gastroenterol* 1995;90:1250-1257.
291. McCormick SE, Goodman ZD, Maydonovitch CL, Sjogren MH: Evaluation of liver histology, ALT elevation, and HCV RNA titer in patients with chronic hepatitis C. *Am J Gastroenterol* 1996;91:1516-1522.
292. Poynard T, Bedossa P, Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. *Lancet* 1997;349:825-832.
293. Oberti F, Valsesia E, Pilette C, et al.: Noninvasive diagnosis of hepatic fibrosis or cirrhosis. *Gastroenterology* 1997;113:1609-1616.

294. Trinchet J-C: Clinical use of serum markers of fibrosis in chronic hepatitis. *J Hepatol* 1995;22(Suppl 2):89-95.
295. Schmidt E, Schmidt FW: Progress in the enzyme diagnosis of liver disease: reality or illusion. *Clin Biochem* 1990;23:375-283.
296. Goldstein NS, Blue DE, Hankin R, et al.: Serum α -fetoprotein levels in patients with chronic hepatitis C – relationship with serum alanine aminotransferase values, histologic activity index, and hepatocyte MIB-1 scores. *Am J Clin Pathol* 1999;111:811-816.
297. Bayati N, Silverman AL, Gordon SC: Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. *Am J Gastroenterol* 1998;93:2452-2456.
298. Bosch FX, Ribes J, Borrás J: The epidemiology of primary liver cancer. *Semin Liv Dis* 1999;19:271-285.
299. El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. *N Engl J Med* 1999;340:745-750.
300. Fattovich F, Giustina G, Schalm SW, et al.: Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. *Hepatology* 1995;21:77-82.
301. Fattovich G, Giustina G, Degos F, et al.: Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. *Gastroenterology* 1997;112:463-472.
302. Zaman SN, Johnson PJ, Williams R: Silent cirrhosis in patients with hepatocellular carcinoma. Implications for screening in high-incidence and low-incidence areas. *Cancer* 1990;65:1607-1610.
303. Izzo F, Cremona F, Ruffolo F, Palaia R, Parisi V, Curley SA: Outcome of 67 patients with hepatocellular carcinoma detected during screening or 1125 patients with chronic hepatitis. *Ann Surg* 1998;227:513-518.
304. Chalasani N, Said A, Ness R, Hoen H, Lumeng L: Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: Results of a national survey. *Am J Gastroenterol* 1999;94:2224-2229.
305. Tong MJ, Blatt LM, Kao VW: Screening and surveillance of chronic viral hepatitis patients for hepatocellular carcinoma: a seven year study using serum alfa-fetalprotein and abdominal ultrasound. *Hepatology* 1999;30:209A.

306. Di Bisceglie AM, Hoofnagle JH: Elevations in serum alpha-fetoprotein in patients with chronic hepatitis B. *Cancer* 1989;64:2117-2110.
307. McMahon BJ, London T: Workshop on screening for hepatocellular carcinoma. *J Natl Cancer Inst* 1991;83:916-919.
308. Riegler JL: Preneoplastic conditions of the liver. *Sem Gastrointest Dis* 1996;7:74-87.
309. Pateron D, Ganne N, Trinchet JC, et al.: Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. *J Hepatol* 1995;22:708-709.
310. Cottone M, Turri M, Caltagirone M, et al.: Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8 year prospective study by ultrasound and alphafetoprotein. *J Hepatol* 1994;21:1029-1034.
311. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S: Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. *Hepatology* 1994;19:61-66.
312. Sarasin FP, Giostra E, Hadengue A: Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. *Am J Med* 1996;101:422-434.
313. Collier J, Sherman M: Screening for hepatocellular carcinoma. *Hepatology* 1998;27:273-278.
314. Sheu JC, Sung JL, Chen DS, et al.: Growth rate of asymptomatic hepatocellular carcinoma and its clinical significance. *Gastroenterology* 1983;89:259-266.
315. Fujiyama S, Morishita T, Hashiguchi O, Sato T: Plasma abnormal prothrombin (des- γ -carboxy prothrombin) as a marker of hepatocellular carcinoma. *Cancer* 1988;61:1621-1628.
316. Liebman HA, Furie BC, Tong MJ, et al.: Des- γ -carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. *N Engl J Med* 1984;310:1427-1431.
317. Nomura F, Ishijima M, Kuwa K, Tanaka N, Nakai T, Ohnishi K: Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. *Am J Gastroenterol* 1999;94:650-654.

318. Shiraki K, Takase K, Tameda Y, et al.: A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. *Hepatology* 1995;22:802-807.
319. Lu Y, Lu Q, Chen HL: Diagnosis of primary liver cancer using lectin affinity chromatography of serum alkaline phosphatase. *J Exp Clin Cancer Res* 1997;16:75-80.
320. Yao D-F, Huang Z-W, Chen S-Z, et al.: Diagnosis of hepatocellular carcinoma by quantitative detection of hepatoma-specific bands of serum γ -glutamyltransferase. *Am J Clin Pathol* 1998;110:743-749.